Nexbridge Pharmaceuticals announced Monday it has agreed to acquire Verano BioSciences in an all-cash transaction valued at approximately $11 billion, a deal that would significantly expand Nexbridge’s oncology portfolio and give the combined company a commanding presence in the rapidly growing field of targeted cancer therapies.
Under the terms of the agreement, Nexbridge will pay $78 per share for Verano, a premium of roughly 34 percent over the smaller company’s closing price on Friday. The deal, which has been unanimously approved by the boards of both companies, is expected to close in the first half of next year, subject to regulatory and shareholder approvals.
Nexbridge Chief Executive Officer Patricia Lander said the acquisition represents a strategic inflection point for the company, which has been seeking ways to diversify beyond its established cardiovascular and metabolic disease franchises. “Verano has built an exceptional platform in precision oncology,” Lander said in a statement. “This combination allows us to bring these therapies to patients faster and at greater scale than either company could achieve independently.”
Verano’s lead asset, a targeted therapy designed to treat a specific form of lung adenocarcinoma, reported strong Phase 3 trial results earlier this year and is currently under review by regulatory authorities. Analysts at Northgate Bioequity Research estimate the drug could generate peak annual revenues of between $3 billion and $4 billion if approved.
The deal also includes a pipeline of eight earlier-stage oncology candidates, which Nexbridge said it intends to accelerate through development. The company said it plans to invest an additional $1.5 billion in research and development related to the acquired assets over the next five years.
Verano’s Chief Executive Officer Carlos Mendes said the transaction provides the resources needed to realize the full potential of the company’s science. “We built Verano from the ground up with the belief that precision medicine would transform oncology,” Mendes said. “Joining Nexbridge gives our programs the global reach and commercial infrastructure they deserve.”
Nexbridge said it expects the acquisition to be modestly dilutive to earnings in the first year following close but meaningfully accretive by the third year, assuming regulatory approval of Verano’s lead compound. The company plans to fund the transaction through a combination of existing cash reserves and new debt financing.
The announcement triggered significant movement in both companies’ shares. Verano stock surged 31 percent to $76.40 in morning trading, approaching but not quite reaching the offer price, reflecting some residual uncertainty about regulatory approval. Nexbridge shares fell 4.2 percent as investors weighed the cost of the acquisition against the long-term strategic rationale.
Analysts offered broadly positive assessments of the deal’s strategic logic. “This is exactly the kind of bolt-on acquisition that Nexbridge needed to sustain its growth trajectory into the next decade,” said Miriam Castillo, a senior analyst at Prescott Healthcare Advisors. “The premium is steep, but Verano’s pipeline justifies it if the lead asset clears regulators.”
The transaction comes amid a wave of consolidation in the pharmaceutical sector, as larger companies seek to replenish pipelines thinning from patent expirations and to acquire novel platforms developed by smaller, more nimble biotech firms. Analysts expect deal activity to remain elevated as cost pressures and competition for differentiated assets intensify.
Nexbridge said it does not anticipate major workforce reductions as a result of the merger, noting that the two companies have limited geographic and functional overlap. Integration planning teams have already been established to prepare for a smooth transition.
The deal represents Nexbridge’s largest acquisition in more than a decade and follows a period in which the company returned substantial capital to shareholders through buybacks and dividends. Lander said the company had been patient in its search for the right asset. “We could have done smaller deals over the past few years, but we held out for something transformative,” she said. “Verano is that company.” Nexbridge’s credit ratings were affirmed by two major rating agencies following the announcement, with both noting that the company’s balance sheet remains investment grade despite the debt taken on to fund the purchase.